嵌合抗原受体
CD19
细胞疗法
医学
临床试验
汽车T细胞治疗
癌症研究
免疫疗法
抗原
免疫学
癌症
细胞
内科学
生物
遗传学
作者
Matthew J. Frigault,Marcela V. Maus
摘要
Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations of novel constructs being developed at a rapid pace. Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in CD19+ B cell malignancies, multiple clinical trials of CAR T cell therapy directed to CD19 have led to the approval of this therapy by the FDA and the European Medicines Agency for specific indications. Despite strikingly similar efficacy, investigators at multiple centers participating in these studies have observed the nuances of each CAR T cell product, including variability in manufacturing, availability, and toxicity profiles. Here we review state-of-the-art clinical data on CD19-directed CAR T cell therapies in B cell hematologic malignancies, advances made in understanding and modeling associated toxicities, and several exciting advances and creative solutions for overcoming challenges with this therapeutic modality.
科研通智能强力驱动
Strongly Powered by AbleSci AI